Research on cost-effectiveness in standard treatment for major depressive disorder

2016 Fiscal Year Final Research Report

• Project/Area Number: 26670544
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Psychiatric science
• Research Institution: Tokyo Women's Medical University
• Principal Investigator: Yamada Kazuo 東京女子医科大学, 医学部, 教授 (70255553)
• Research Collaborator: KAMAGATA Eiichiro
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 月経前不快気分障害（ＰＭＤＤ） / ＥＱ－５Ｄ / 質調整生存年（ＱＡＬＹ） / 生活の質（ＱＯＬ） / 直接コスト / 増分費用対効果（ＩＣＥＲ） / 費用対効果受容曲線（ＣＥＡＣ） / 支払意思額

Outline of Final Research Achievements

This research aimed to examine the loss of the quality adjusted life years (QALYs) in patients with premenstrual dysphoric disorder (PMDD), which is classified as a depressive disorder, and to investigate the cost-effectiveness of pharmacotherapy for PMDD. It was calculated that the expected mean loss of QALYs was about 0.2 years. Pharmacotherapy produced an improvement of approximately 0.2 QALYs. It was thought that the pharmacotherapy was cost-effective for the treatment of PMDD, since the cost-effectiveness of pharmacotherapy was calculated to be 823,000 yen per QALY. A cost-effectiveness acceptability curve analysis indicated that escitalopram tended to be superior to sertraline when willingness to pay per QALY was over 4,000,000 yen, whereas sertraline was superior when willingness to pay was below 2,000,000 yen.

Free Research Field

精神医学